The launch of a new European clinical trial network in September will aid in the battle to combat antimicrobial resistance by delivering rapid, high quality research studies. The European Clinical Research Alliance for Infectious Diseases (ECRAID) features a coordinated, single-point-of-access model that aims to streamline infectious diseases research, reduce costs, and accelerate medical advancements.
The EU-funded ECRAID-Base project is supporting the ongoing development of ECRAID into an independent, self-sustaining, not-for-profit organization over the next five years.
ECRAID’s infrastructure combines networks built by the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) program and the Combatting Bacterial Resistance in Europe (COMBACTE) consortium. The ARLG and COMBACTE have been collaborative partners since 2019. Herman Goossens, who has been a proponent of improving European clinical trial efficiencies by increasing collaboration, is spearheading ECRAID’s vision by serving as its executive director and CEO.